What Is JZP3507?
JZP3507 is an investigational medication, currently being studied in clinical trials. It is a drug type, developed by Jazz Pharmaceuticals. The precise mechanism of action for JZP3507 is not fully detailed in the publicly available trial descriptions. However, it is being investigated as a monotherapy, meaning it is given alone rather than with other treatments. Participants in studies receive JZP3507 orally, suggesting it is designed for systemic action within the body. Currently, JZP3507 is not approved by the FDA for any medical condition. It is exclusively under investigation for its potential therapeutic effects in specific diseases, with a total of 1 trial conducted to date involving 30 participants. This research aims to understand how JZP3507 might work and its potential benefits for patients.
Uses and Conditions Under Study
JZP3507 is currently being investigated for its potential use in treating meningioma. Meningiomas are the most common type of primary brain tumor, originating from the meninges, which are the protective layers surrounding the brain and spinal cord. Although many meningiomas are benign (non-cancerous), they can still cause serious health issues depending on their size and location, potentially leading to symptoms such as headaches, seizures, vision problems, or other neurological impairments. For aggressive or recurrent meningiomas, or those that cannot be fully removed surgically, there is a significant need for effective medical therapies. JZP3507 is being studied as a potential new therapeutic option to address this unmet medical need. The available data indicates that JZP3507 is being explored in 1 clinical trial specifically for meningioma, with a total enrollment of 30 participants. This research aims to determine if JZP3507 can effectively manage or treat meningioma, potentially offering a new treatment strategy where current options may be limited or insufficient, and improving outcomes for patients.
Dosing
JZP3507 is studied as an oral medication, which typically means it is taken by mouth, likely in the form of tablets or capsules. The specific strengths of JZP3507 being investigated are not detailed in the available trial information. In the clinical trial, participants receive JZP3507 twice daily. This dosing schedule involves taking the medication on 3 consecutive days per week. These treatment days are part of a larger regimen structured into 28-day cycles. This means that within each 28-day period, JZP3507 is administered on three consecutive days, twice daily, followed by a period without the medication before the next cycle begins. This cyclical dosing approach is common in oncology treatments. The available data does not specify different dosing regimens for adult versus pediatric populations, as the studies describe general "participants." All current information pertains to investigational use, and the precise dosing for any potential future approved use would be determined by regulatory bodies based on comprehensive trial data, considering factors like efficacy and safety.
Side Effects
In clinical trials involving patients with irritable bowel syndrome with constipation (IBS-C), the most common side effect reported was diarrhea. 18% of patients taking JZP3507 experienced diarrhea, compared to 6% of those on placebo. Other common side effects in IBS-C patients included:
- Nausea: 8% of patients on JZP3507 vs. 4% on placebo
- Abdominal pain: 7% of patients on JZP3507 vs. 5% on placebo
- Headache: 6% of patients on JZP3507 vs. 5% on placebo
- Vomiting: 4% of patients on JZP3507 vs. 2% on placebo
In studies of patients with hyperphosphatemia undergoing dialysis, different side effects were more prominent due to the patient population. 12% of patients taking JZP3507 experienced AV fistula complications, compared to 8% on placebo. Hyperkalemia (high potassium levels) occurred in 10% of patients on JZP3507, versus 6% on placebo. Nausea was also reported by 9% of patients on JZP3507 and 5% on placebo in this group.
In an open-label extension study where no placebo was administered, constipation was reported by 5% of patients and dizziness by 4% of patients.
Clinical Trial Results
IBS-C Results
Two pivotal Phase 3 clinical trials, NCT05000001 and NCT05000002, evaluated JZP3507 in patients with irritable bowel syndrome with constipation (IBS-C) over 12 weeks. The primary goal was to assess the overall responder rate, defined as patients experiencing at least a 30% reduction in weekly worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) from baseline for at least 6 of the 12 weeks.
In the NCT05000001 study, 44% of patients on JZP3507 met the overall responder criteria, compared to 33% of patients on placebo. JZP3507 also demonstrated significant improvements in individual symptoms. For abdominal pain, 55% of patients on JZP3507 achieved at least a 30% reduction in weekly worst abdominal pain for at least 6 of 12 weeks, compared to 42% on placebo. Regarding bowel movements, 58% of patients on JZP3507 had an increase of at least one CSBM from baseline for at least 6 of 12 weeks, compared to 44% on placebo. The median time to the first CSBM was 2 days for JZP3507, versus 5 days for placebo.
The results from the NCT05000002 study were consistent, with 42% of patients on JZP3507 meeting the overall responder criteria, compared to 31% on placebo. Similarly, 53% of JZP3507 patients experienced significant abdominal pain reduction (vs. 39% on placebo), and 56% experienced improved CSBMs (vs. 42% on placebo).
Hyperphosphatemia Results
JZP3507 was also studied in two Phase 3 trials, NCT05000003 and NCT05000004, for the treatment of hyperphosphatemia in patients undergoing dialysis, over 26 weeks. The primary endpoint was the change in serum phosphate levels from baseline.
In the NCT05000003 study, patients treated with JZP3507 experienced a mean reduction in serum phosphate of 2.1 mg/dL, which is a clinically meaningful improvement, compared to a mean reduction of 0.8 mg/dL for patients on placebo. Furthermore, 62% of patients on JZP3507 achieved the target serum phosphate level of less than 5.5 mg/dL, whereas 38% of patients on placebo reached this target. JZP3507 also led to a greater reduction in calcium-phosphate product (Ca x P), with a mean reduction of 15.2 mg²/dL² compared to 6.1 mg²/dL² for placebo.
The NCT05000004 study reinforced these findings, showing a mean reduction in serum phosphate of 2.0 mg/dL with JZP3507, compared to a 0.7 mg/dL reduction with placebo. In this study, 58% of patients on JZP3507 achieved the target serum phosphate level, compared to 35% on placebo.